Results 21 to 30 of about 118,147 (316)

Biologics: the role of delivery systems in improved therapy [PDF]

open access: yes, 2014
Nataša Škalko-Basnet Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Tromsø, Norway Abstract: The beginning of the 21st century saw numerous protein and peptide therapeuticals both on
Škalko-Basnet N   +1 more
core   +1 more source

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface

open access: yesmAbs, 2023
Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities.
John D. Bagert   +22 more
doaj   +1 more source

Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells

open access: yesOncoImmunology, 2019
Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20–40% of patients to generate anti-tumor immune responses.
Maxine Bauzon   +5 more
doaj   +1 more source

Engineered Fc-glycosylation switch to eliminate antibody effector function

open access: yesmAbs, 2020
Antibodies mediate effector functions through Fcγ receptor (FcγR) interactions and complement activation, causing cytokine release, degranulation, phagocytosis, and cell death. They are often undesired for development of therapeutic antibodies where only
Qun Zhou   +13 more
doaj   +1 more source

Comprehensive modeling of cell culture profile using Raman spectroscopy and machine learning

open access: yesScientific Reports, 2023
Chinese hamster ovary (CHO) cells are widely utilized in the production of antibody drugs. To ensure the production of large quantities of antibodies that meet the required specifications, it is crucial to monitor and control the levels of metabolites ...
Hiroki Tanemura   +5 more
doaj   +1 more source

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

open access: yesJournal for ImmunoTherapy of Cancer, 2022
Background Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher ...
Frank Nestle   +16 more
doaj   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

open access: yesNature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang   +12 more
doaj   +1 more source

A potential new biological marker of the biological age [PDF]

open access: yesFrontiers in Genetics, 2013
For many years, data have been accumulated which point to a significant similarity between the nature of the brain damage in the aging process (in the case of dementia or even in outwardly healthy elderly people) and the brain damage caused by prion diseases of humans and animals (Sobel, 1970; Fraser and McBride, 1985; Masters et al., 1985; Gajdusek ...
Zuev, Victor A.   +2 more
openaire   +3 more sources

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

open access: yes, 2023
Background: Treatment of hidradenitis suppurativa (HS) is difficult and current guidelines are based mainly on expert opinion and non-randomized controlled trials.
Tsen-Fang Tsai   +2 more
core   +1 more source

Engineering an anti-CD52 antibody for enhanced deamidation stability

open access: yesmAbs, 2019
Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity ...
Huawei Qiu   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy